Skip to main content

Vertex Pharmaceuticals Inc

VRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000875320

In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 3 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vertex Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
3 insiders, $2.00M in total
Insiders trading
3
Net value
−$2.00M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vertex Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vertex Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
van Grunsven JasperEVP, CP and NPPO8,682Sep 10, 20261
Ambrose KristenSVP & Chief Accounting Officer11,624Sep 1, 20267
Sachs Bruce IDirector39,000Aug 31, 20266
Tatsis OuraniaEVP, Chief Reg. & Quality Off.53,572Jul 23, 20269
Sachdev AmitEVP Chief Patient & Ext Af Off66,512Jul 23, 20267
Garber Alan MDirector7,344Jul 17, 20263
McKechnie DuncanEVP, Chief Commercial Officer11,001Jul 7, 20268
Liu JoyEVP and Chief Legal Officer19,131Jul 6, 20265
Bozic CarmenEVP and CMO15,337Jun 30, 202615
Bunnage Mark E.EVP, Chief Scientific Officer7,284May 19, 20265
Carney LloydDirector6,315May 5, 20262
Lagarde MichelDirector1,132May 5, 20261
Upadhyay SuketuDirector1,558May 5, 20264
Bhatia Sangeeta N.Director4,924May 5, 20262
McKenzie DianaDirector2,378May 5, 20261
Schneider JenniferDirector1,394May 5, 20261
Thornberry NancyDirector2,109May 5, 20261
Kewalramani ReshmaCEO & President98,278Mar 3, 20266
Wagner Charles F JrEVP, CO & FO47,042Feb 26, 20267
Leiden Jeffrey MExecutive Chairman34,797Feb 26, 20265
Biller JonathanEVP and Chief Legal Officer13,659Feb 26, 20267
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.18,432Feb 26, 20266
Altshuler DavidEVP, Chief Scientific Officer34,477Jan 26, 20261
Arbuckle Stuart AEVP, COO63,368Jul 2, 20250
Kearney Terrence CDirector6,536May 3, 20240
Sanna BastianoEVP, Cell & Genetic Therapies32,038May 9, 20230
McGlynn Margaret GDirector178May 3, 20230
Lee YuchunDirector1,875May 3, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 4, 2021 (view filing)Aug 22 daysSachs Bruce IDirectorPPurchase+15.0K$197.91+$2.97M+57.2%41.2K after
Aug 23, 2021 (view filing)Aug 194 daysKewalramani ReshmaCEO & PresidentPPurchase+10.0K$195.65+$1.96M+15.7%73.8K after2 lots
Nov 16, 2021 (view filing)Nov 151 dayAltshuler DavidEVP, Global Research and CSOSSale−34$187.22−$6.37K−0.1%33.6K after2 lots
Nov 16, 2021 (view filing)Nov 151 dayArbuckle Stuart AEVP, COOSSale−3$187.26−$561.780.0%41.1K after2 lots
Nov 16, 2021 (view filing)Nov 151 daySachdev AmitEVP, Chief Patient OfficerSSale−51$187.19−$9.55K−0.2%31.9K after2 lots
Feb 1, 2022 (view filing)Jan 284 daysMcGlynn Margaret GDirectorSSale−5.00K$241.79−$1.21M−82.0%1.10K after4 lots
Feb 3, 2022 (view filing)Feb 21 dayAltshuler DavidEVP, Global Research and CSOSSale−4.66K$251.47−$1.17M−6.6%65.7K after7 lots
Feb 3, 2022 (view filing)Feb 21 daySanna BastianoEVP, Cell & Genetic TherapiesSSale−1.04K$250.98−$261.0K−1.9%55.0K after5 lots
Feb 3, 2022 (view filing)Feb 21 dayWagner Charles F JrEVP & Chief Financial OfficerSSale−2.94K$250.07−$736.2K−4.9%57.4K after
Feb 14, 2022 (view filing)Feb 113 daysAltshuler DavidEVP, Global Research and CSOSSale−2.30K$235.02−$539.8K−3.7%59.9K after4 lots
Feb 14, 2022 (view filing)Feb 113 daysTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−290$235.09−$68.2K−0.5%57.7K after4 lots
Feb 16, 2022 (view filing)Feb 142 daysAltshuler DavidEVP, Global Research and CSOSSale−2.44K$232.02−$567.1K−4.1%57.4K after
Feb 22, 2022 (view filing)Feb 184 daysAltshuler DavidEVP, Global Research and CSOSSale−4.31K$230.97−$995.9K−8.0%49.7K after5 lots
Feb 22, 2022 (view filing)Feb 184 daysTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−519$231.00−$119.9K−1.0%53.1K after4 lots
Feb 28, 2022 (view filing)Feb 253 daysAltshuler DavidEVP, Global Research and CSOSSale−7.57K$230.98−$1.75M−17.3%36.1K after4 lots
Feb 28, 2022 (view filing)Feb 253 daysTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−325$230.95−$75.1K−0.6%50.2K after5 lots
Mar 21, 2022 (view filing)Mar 174 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−2.12K$250.06−$530.6K−4.2%48.4K after
Mar 21, 2022 (view filing)Mar 174 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−3.17K$250.15−$793.2K−6.4%46.2K after2 lots
Mar 21, 2022 (view filing)Mar 174 daysTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−2.83K$250.11−$708.6K−5.6%47.4K after2 lots
Apr 4, 2022 (view filing)Mar 314 daysMcGlynn Margaret GDirectorSSale−5.00K$262.27−$1.31M−82.0%1.10K after3 lots
Apr 5, 2022 (view filing)Apr 14 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−2.58K$264.76−$683.6K−5.6%43.6K after5 lots
Apr 6, 2022 (view filing)Apr 4-52 daysLee YuchunDirectorSSale−4.00K$270.11−$1.08M−68.1%1.88K after9 lots
Apr 6, 2022 (view filing)Apr 4-52 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−3.73K$274.10−$1.02M−7.9%43.3K after3 lots
Apr 8, 2022 (view filing)Apr 71 daySanna BastianoEVP, Cell & Genetic TherapiesSSale−561$276.18−$154.9K−1.3%42.8K after3 lots
Apr 8, 2022 (view filing)Apr 6-72 daysLee YuchunDirectorSSale−4.00K$273.24−$1.09M−68.1%1.88K after9 lots
Apr 12, 2022 (view filing)Apr 84 daysMcGlynn Margaret GDirectorSSale−5.00K$280.22−$1.40M−82.0%1.10K after2 lots
Apr 12, 2022 (view filing)Apr 84 daysBhatia Sangeeta N.DirectorSSale−1.91K$280.20−$534.3K−26.9%5.19K after
Apr 12, 2022 (view filing)Apr 8-114 daysLee YuchunDirectorSSale−4.00K$279.43−$1.12M−68.1%1.88K after7 lots
Apr 14, 2022 (view filing)Apr 12-132 daysLee YuchunDirectorSSale−4.00K$284.27−$1.14M−68.1%1.88K after12 lots
Apr 14, 2022 (view filing)Apr 131 dayLeiden Jeffrey MExecutive ChairmanSSale−15.8K$289.04−$4.56M−17.6%74.2K after
Apr 18, 2022 (view filing)Apr 144 daysLee YuchunDirectorSSale−2.00K$289.06−$578.1K−51.6%1.88K after4 lots
Apr 20, 2022 (view filing)Apr 182 daysLee YuchunDirectorSSale−2.00K$284.23−$568.5K−51.6%1.88K after4 lots
Apr 27, 2022 (view filing)Apr 252 daysAmbrose KristenSVP & Chief Accounting OfficerSSale−327$269.55−$88.1K−8.6%3.50K after4 lots
May 3, 2022 (view filing)Apr 294 daysLiu JoySVP, General CounselSSale−120$275.41−$33.0K−0.8%14.3K after5 lots
May 4, 2022 (view filing)May 22 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−343$258.83−$88.8K−0.8%42.7K after7 lots
May 4, 2022 (view filing)May 22 daysBhatia Sangeeta N.DirectorSSale−737$258.94−$190.8K−11.1%5.90K after7 lots
May 4, 2022 (view filing)May 22 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−320$259.16−$82.9K−0.8%41.7K after7 lots
May 4, 2022 (view filing)May 22 daysArbuckle Stuart AEVP, COOSSale−306$263.98−$80.8K−0.5%64.8K after
May 6, 2022 (view filing)May 42 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−36$275.09−$9.90K−0.1%41.7K after
May 18, 2022 (view filing)May 162 daysLiu JoySVP, General CounselSSale−133$252.88−$33.6K−0.9%14.3K after5 lots
May 18, 2022 (view filing)May 162 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−45$252.83−$11.4K−0.1%41.7K after5 lots
May 18, 2022 (view filing)May 162 daysArbuckle Stuart AEVP, COOSSale−133$251.19−$33.4K−0.2%64.8K after7 lots
Jun 28, 2022 (view filing)Jun 244 daysKewalramani ReshmaCEO & PresidentSSale−11.7K$291.30−$3.41M−9.5%111.2K afterFrom original
Jul 21, 2022 (view filing)Jul 192 daysAltshuler DavidEVP, Global Research and CSOSSale−17.9K$288.65−$5.16M−33.1%36.1K after4 lots
Jul 27, 2022 (view filing)Jul 252 daysLeiden Jeffrey MExecutive ChairmanSSale−132.1K$281.38−$37.2M−98.2%2.42K after5 lots
Aug 2, 2022 (view filing)Jul 294 daysBhatia Sangeeta N.DirectorSSale−621$278.77−$173.1K−10.5%5.28K after6 lots
Aug 10, 2022 (view filing)Aug 91 dayArbuckle Stuart AEVP, COOSSale−5.69K$300.67−$1.71M−8.5%61.0K after2 lots
Aug 10, 2022 (view filing)Aug 82 daysAltshuler DavidEVP, Global Research and CSOSSale−1.30K$292.54−$381.5K−3.5%36.1K after5 lots
Aug 10, 2022 (view filing)Aug 91 dayTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−1.40K$298.97−$418.6K−2.9%46.1K after5 lots
Aug 10, 2022 (view filing)Aug 91 dayLiu JoySVP, General CounselSSale−946$300.00−$283.8K−6.6%13.4K after